EnteroBiotix
EnteroBiotix50
About
What does EnteroBiotix do?
EnteroBiotix is a clinical-stage microbiome therapeutics company focused on transforming the standard of care for patients with gastrointestinal disease. Their lead investigational product, EBX-102-02, is an orally delivered, full-spectrum microbiome drug in clinical development for irritable bowel syndrome (IBS) and other gastrointestinal and liver-related diseases. EBX-102-02 is a high-diversity microbial product manufactured using proprietary AMPLA™ drying technology.
What is EnteroBiotix's revenue?
StartupHub estimates EnteroBiotix's annual revenue at $5.1M (range $1.8M to $17.7M, 34% confidence), based on comparable companies in the sector.
What is EnteroBiotix's valuation?
StartupHub estimates EnteroBiotix's effective valuation at $152.3M (range $101.3M to $243.0M, 23% confidence), based on comparable companies in the sector.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $41M in funding. The most recent round on record is Funding Round.
Where is EnteroBiotix headquartered?
EnteroBiotix is headquartered in Glasgow, United Kingdom.
When was EnteroBiotix founded?
EnteroBiotix was founded in 2017.
What industry does EnteroBiotix operate in?
EnteroBiotix operates in Biotechnology, Pharmaceuticals, Healthcare, Life Sciences, Microbiome, Biotech.
No comments yet. Be the first to share your take.